PUBLIC COMPANY
saveSHIONOGI
USupdated 2mo ago
community read0 votes
pipeline
0
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(0)
no pipeline products on record
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase3A Study of Secutrelvir in Participants With Coronavirus Disease 2019 (COVID-19) Who Are at High Risk for Progression to Severe Disease
- phase1Study of S-892216 Long-acting Injectable (LAI) in Healthy Adult Participants
- phase2An Extension Study of S-606001 in Participants With Late-onset Pompe Disease (LOPD)
- phase2A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease
- phase1A Study of S-892216-PO in Participants With Renal Impairment and Matched Controls
- phase3A Study to Compare S-217622 With Placebo in Non-Hospitalized Participants With COVID-19
- phase2A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke
- phase3Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis
🐶 Hiring Signal
News
- Genmab and AbbVie’s Epkinly win, a rush of deals, Sarepta’s turnaround hopes, moreNew data for Genmab and AbbVie’s bispecific antibody Epkinly wowed analysts and could set the partners up for an expanded approval in diffuse large B cell lymphoma; deals have flowed steadily this…biospace · 20d ago
- STAT+: AstraZeneca opens new Boston siteAstraZeneca opened a new R&D site in Kendall Square yesterday, celebrating a $1 billion investment in the unsettled center of U.S. biotechnology after a spate of Chinese dealmaking.stat · 21d ago
- Shionogi makes $2B rare disease play with IntraBio buyWith its acquisition of IntraBio, Shionogi will gain ownership over Aqneursa, which could hit peak global sales of $1 billion across its two indications in Niemann-Pick disease type C and ataxia-te…biospace · 21d ago
- Shionogi pays $2B to acquire a rare disease startupThe acquisition of Texas-based IntraBio adds to a growing rare disease business for Shionogi by handing the company a marketed treatment for two inherited conditions.biopharma_dive · 22d ago
- Shionogi to pay $2B for IntraBio, a commercial rare disease biotechShionogi is buying an Austin, TX-based commercial biotech for $2 billion upfront, adding another medicine to the Japanese pharma's rare disease portfolio. The drugmaker is scooping up IntraBio and…endpoints · 22d ago
- Shionogi's stroke drug fails mid-stage; Bayer's Hyrnuo gets expanded labelPlus news about Tevard Biosciences, InduPro, EMD Serono, Shionogi, Bayer's Hyrnuo. Disc's competitor for Takeda's blood disorder drug Mimrylo: Disc Medicine shared initial data from its Phase 2 RES…endpoints · 1mo ago
- Sanofi to ‘rebuild trust’ with Regeneron; Apnimed adds to string of ‘upsized’ biotech IPOsSanofi wants to broaden the company’s productive partnership with Regeneron, its CEOs said. Elsewhere, Bristol Myers delayed two anticipated study readouts and a Shionogi-backed startup went public.biopharma_dive · 2mo ago
- Apnimed’s IPO dream comes true with upsized $192M IPO to fund sleep apnea pill launchApnimed has raised $192 million for its upsized IPO, with the proceeds earmarked to fund the launch of its sleep apnea pill.fiercebiotech · 2mo ago
- Antifungal from F2G, Shionogi succeeds in Phase 3 studyF2G and Shionogi released positive Phase 3 data on Thursday morning, giving the companies a potentially clear path to approval for their antifungal drug. The companies said their treatment called o…endpoints · 4mo ago
- Shionogi wins US approval for first pill to prevent Covid following exposureJapan's Shionogi on Monday said it won FDA approval for its oral antiviral to prevent Covid‑19 in adults and children older than 12 years who have been in contact with someone ...endpoints · 4mo ago
comments(0)
5-min edit window · permanent after that